Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab.
Journal Information
Full Title: CPT Pharmacometrics Syst Pharmacol
Abbreviation: CPT Pharmacometrics Syst Pharmacol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"CONFLICT OF INTEREST STATEMENT N.Z., J.L., P.Z.B., B.S., I.V., L.K.R., and R.F. were employees of AstraZeneca and own stock in AstraZeneca at the time the study was conducted or the manuscript was being prepared. All other authors declared no competing interests for this work."
Funding Disclosure
Evidence found in paper:
"FUNDING INFORMATION The study was supported by Catalyst Award for Therapeutic Project between March 1, 2016 and June 30, 2019."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025